Gursharan Singh

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 8

Top Topics

Recombinant Human

Insulin Resistance

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Grit Andersen, Gursharan Singh, Sundara Moorthi Nainar Murugesan, Rajesh Gogineni, Nirant Sharma, Jayanti Panda, Ashwani Marwah, Subramanian Loganathan, Sandeep N Athalye
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. Diabetes, obesity & metabolism (2023)
Grit Andersen, Gursharan Singh, Sundara Moorthi Nainar Murugesan, Rajesh Gogineni, Nirant Sharma, Jayanti Panda, Ashwani Marwah, Subramanian Loganathan, Sandeep N Athalye
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. Diabetes, obesity & metabolism (2023)
Shashank R Joshi, Gursharan Singh, Ashwani Marwah, Shivani Mittra, Viraj R Suvarna, Sandeep N Athalye
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis. Diabetes, obesity & metabolism (2023)
Grit Andersen, Gursharan Singh, Sundara Moorthi Nainar Murugesan, Rajesh Gogineni, Nirant Sharma, Jayanti Panda, Ashwani Marwah, Subramanian Loganathan, Sandeep N Athalye
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. Diabetes, obesity & metabolism (2023)
Shashank R Joshi, Gursharan Singh, Ashwani Marwah, Shivani Mittra, Viraj R Suvarna, Sandeep N Athalye
Comparative clinical efficacy and safety of insulin glargine 300 U/mL (Toujeo) versus insulin glargine 100 U/mL in Type 2 and Type 1 diabetes mellitus: A systematic literature review and meta-analysis. Diabetes, obesity & metabolism (2023)
Shashank R Joshi, Gursharan Singh, Ashwani Marwah, Shivani Mittra, Viraj R Suvarna, Sandeep N Athalye
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis. Diabetes, obesity & metabolism (2023)
Leona Plum-Mörschel, Oliver Klein, Gursharan Singh, Sundara Moorthi Nainar Murugesan, Ashwani Marwah, Nirant Sharma, Jayanti Panda, Subramanian Loganathan, Gopu Chandrasekharan Lakshmi, Sandeep N Athalye
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study. Diabetes, obesity & metabolism 24 (9) (2022)
Leona Plum-Mörschel, Gursharan Singh, Sundara Moorthi Nainar Murugesan, Ashwani Marwah, Jayanti Panda, Subramanian Loganathan, Sandeep N Athalye
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study. Diabetes, obesity & metabolism 24 (4) (2022)